Clinical Trials Logo
  1. Home
  2. Angelman Syndrome
  3. NCT05011851

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome — AS-001  

Angelman Syndrome Clinical Trial

Official title:
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Clinical Trial Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Clinical Trial Description

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution, 50mg/L, in children and adolescents with Angelman syndrome. The secondary purpose is to investigate measures of efficacy of subjects will receive treatment of 50mg/mL orally administered NNZ-2591 for a total of 13 weeks ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05011851
Study type Interventional
Source Neuren Pharmaceuticals Limited
Contact Fernanda Cecchin
Phone +61 2 9171 3274
Email Fernanda.Cecchin@novotech-cro.com
Status Recruiting
Phase Phase 2
Start date July 12, 2022
Completion date June 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05293184 - The Global Angelman Syndrome Registry
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06229769 - Natural History Study for Patients With Angelman Syndrome
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Recruiting NCT05100810 - Angelman Syndrome Natural History Study-FAST UK
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Recruiting NCT06337383 - Study of the Prevalence of Autistic Traits in Angelman Syndrome
Recruiting NCT05945576 - IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Recruiting NCT05630066 - Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Phase 2
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Terminated NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 3
Completed NCT02996305 - A Study in Adults and Adolescents With Angelman Syndrome (STARS) Phase 2
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3